Table 3 Adverse events during consolidation treatment, n (%).
Total N = 175 | ATO N = 85 | RIF N = 90 | p | |
|---|---|---|---|---|
Infection/FUO | 60 (34.3) | 36 (42.4) | 24 (26.7) | 0.029 |
PCT | 48 (27.4) | 29 (34.1) | 19 (21.1) | 0.063 |
Coagulopathy events | ||||
Hemorrhage | 7 (4.0) | 5 (5.9) | 2 (2.2) | 0.267 |
Thrombosis | 2 (1.1) | 1 (1.2) | 1 (1.1) | 1.000 |
Liver | ||||
Grade 1–2 | 5 (2.9) | 2 (2.4) | 3 (3.3) | 1.000 |
Grade 3–4 | 0 (0) | 0 (0) | 0 (0) | - |
Cardiaca | ||||
Grade 1–2 | 3 (1.7) | 3 (3.5) | 0 (0) | 0.112 |
Grade 3–4 | 1 (0.6) | 1 (1.2) | 0 (0) | 0.486 |
Gastrointestinal dysfunction | ||||
Grade 1–2 | 27 (15.4) | 11 (12.9) | 16 (17.8) | 0.376 |
Grade 3–4 | 0 (0) | 0 (0) | 0 (0) | - |
Rash | 2 (1.1) | 1 (1.2) | 1 (3.3) | 1.000 |
